Externally funded Projects
In 2019/2020, Paul-Ehrlich-Institut raised over 4 Million Euros more in third-party-funding than in 2017/2018
BMG | Federal Ministry of Health (2.619.235 €)
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Dr Christoph Conrad | GHPP Global Health Protection Programme RegTrain-VaccTrain: Regulatory training and consulting for vaccines and biomedical therapeutics | 01.01.19 - 31.12.20 |
| Dr Anneliese Hilger | GHPP Global Health Protection Programme BloodTrain: Availability, safety and quality of blood and blood products | 01.01.19 - 31.12.20 |
| Prof. Dr Gerald G. Schumann | Safety of human pluripotent stem cells used for somatic cell therapy | 01.01.19 - 31.12.21 |
BMBF | Federal Ministry of Education and Research (2.068.550 €)
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Dr Christoph Conrad | PDU CARB-X-Accelerator: Project management, consulting and regulatory aspects of antibiotic development | 01.01.19 - 31.12.21 |
| Dr Christoph Conrad | DZIF-OSRA: German Center for Infection Research - Office for Scientific and Regulatory Advice | 01.01.19 - 28.02.21 |
| Prof. Dr Eberhard Hildt | Hepatitis B Cure: Development of a therapeutic vaccine against HBV based on HBV antigen-presenting cell-permeable VLPs | 01.01.19 - 28.02.21 |
| PD Dr Michael Mühlebach | Recombinant measles virus as vaccine platform | 01.01.19 - 28.02.21 |
| Prof. Dr Isabelle Bekeredjian-Ding | COMBINE: Collaboration for prevention and treatment of MDR bacterial infections - Preparation of a IMI-EU application phase II | 01.02.19 - 31.12.19 |
| Prof. Dr Stefan Vieths | DIFAMEM: Dietary intervention in food allergy - microbiome, epigenetic and metabolomic interactions | 01.03.19 - 28.02.22 |
| Dr Heike Behrensdorf-Nicol Dr Birgit Kegel | Alternative methods to animal testing: BoNT collaborative study on the implementation of the BINACLE assay for in vitro activity determination of botulinum neurotoxins | 01.04.19 - 31.03.21 |
| Prof. Dr Isabelle Bekeredjian-Ding | Alternative methods to animal testing: B-CELL-ACT - Functional assay for B cell activation by toxoid vaccines | 01.04.19 - 31.03.22 |
| Dr Verena Klümpers PD Dr Micha Nübling Dr Alexander Pinz | BISKIT: Blood Information System for Crisis Intervention and Management Subprojekt: Processes und Structure | 01.04.20 - 31.03.23 |
| PD Dr Michael Mühlebach | MeV-derived vaccine candidates protecting against COVID-19 | 15.04.20 - 14.04.21 |
DFG | German Research Foundation (2.115.295 €)
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Dr Stephan Scheurer | Immune modulating mechanisms of flagellin A (FlaA)-fusion proteins at the interface between cell metabolism, TLR signaling, and inflammasome activation WP2: TLR5/NLRC4-mediated activation | 01.03.19 - 28.02.22 |
| PD Dr Stefan Schülke | Immune modulating mechanisms of flagellin A (FlaA)-fusion proteins at the interface between cell metabolism, TLR signaling, and inflammasome activation WP1: Immune metabolism | 01.05.19 - 30.04.22 |
| PD Dr Thorsten Jürgen Maier | Studies on novel cysteine-reactive nitro fatty acids with covalent attack on inflammation-related drug targets | 01.11.19 - 31.10.22 |
| Prof. Dr Zoltan Ivics | Modeling cerebellar pathology in ataxia-telangiectasia: study of ATM-deficient mice versus human iPS cells | 01.01.20 - 31.12.22 |
| Prof. Dr Dr Ute Modlich | Hematopoietic stem cell-directed gene therapy for the treatment of ataxia telangiectasia (A-T) | 01.04.20 - 31.03.23 |
| Prof. Dr Dr Ute Modlich | Epcr expression and Epcr/Par1 signaling pathways in Mpl-deficient and normal hematopoiesis during transplantation | 01.06.20 - 31.05.23 |
| Prof. Dr Ralf Reinhard Tönjes | Biology of xenogeneic cell, tissue and organ transplantation from basic research to clinical application. | 01.07.20 - 30.06.24 |
| Dr Renate König | Investigation into the cellular mechanisms of the PQBP1-mediated innate immune response to HIV-1 | 01.10.20 - 30.09.23 |
| Prof. Dr Ger van Zandbergen | Cell death dependence of leishmanial exit from infected host macrophages | 01.12.20 - 30.11.23 |
EU | European Union (3.638.280 €)
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Prof. Dr Christian Buchholz | STACCATO: Enhancing the manufacture of advanced biological medicine through high-resolution analysis of single cells | 01.01.19 - 31.12.22 |
| Bettina Ziegele | STARS: Strengthening Training of Academia in Regulatory Sciences and supporting regulatory scientific advice | 01.01.19 - 31.12.21 |
| Prof. Dr Eberhard Hildt | ERASMUS Grant Patrycja Dudek: Characterization of turnover of HCV non-structural proteins | 08.07.19 - 21.09.19 01.10.19 - 15.05.20 |
| Prof Dr Ger van Zandbergen | ERASMUS Grant Fenja Gierschek: Characterization of immunomodulatory conditions in a human in vitro Leishmania infection model | 02.09.19 - 31.01.20 |
| Prof. Dr Isabelle Bekeredjian-Ding | Collaboration for prevention and treatment of multidrug resistent (MDR) bacterial infections | 01.11.19 - 31.10.25 |
| PD Dr Benjamin Hofner | Integrated research platforms enabling patient-centric drug development | 01.11.19 - 30.04.23 |
| Prof. Dr Zoe Waibler | Emerging translational safety technologies and tools for interrogating human immuno-biology | 01.11.19 - 31.10.25 |
| Prof. Dr Isabelle Bekeredjian-Ding | TIPAT: Training towards Personalized Antibiotic Treatment | 01.03.20 - 29.02.24 |
LOEWE Centers, Federal State of Hesse (486.850 €)
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Prof. Dr Christian Buchholz | Frankfurt Cancer Institute: Assessing a CD3-targeted vector for in vivo CAR T cell generation | 01.01.19 - 31.12.19 |
| Prof. Dr Zoltan Ivics | Frankfurt Cancer Institut: CAR NK cell engineering using non-viral Sleeping Beauty transposition for novel design of therapy against malignant disease | 01.01.19 - 31.12.19 |
| Prof. Dr Eberhard Hildt | Novel Drug Targets against Poverty-Related and Neglected Tropical Infectious Diseases (DRUID): Control of Arbovirus infection by interference with the early infection steps | 01.07.19 - 30.09.20 |
| Prof. Dr. Barbara Schnierle | DRUID: Implementation of a Chikungunya virus vaccine candidate based on self-amplifying RNA | 01.10.19 - 30.09.20 01.10.20 - 30.09.21 |
| Dr Daniela Bender | DRUID: Characterisaton of the ZIKV/host interaction | 01.12.19 - 31.05.20 |
| Prof. Dr Jacomina Krijnse-Locker | DRUID: Correlated light- and electron microscopy reveals virus entry and disassembly | 01.01.20 - 31.12.21 |
| Prof. Dr Eberhard Hildt | DRUID: New aspects of established drugs - cholesterol modulators efficiently block HEV replication | 01.07.20 - 31.12.21 |
| Prof Dr Ger van Zandbergen | DRUID: Parallel in vitro and in silico screening of small-molecule libraries against the key Leishmania enzyme glucose-6-phosphate dehydrogenase to identify first lead candidates | 01.07.20 - 31.12.21 |
Foundation and other Organisation (1.336.594 €)
ISBT | International Society of Blood Ttransfusion
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Dr Marcel Prax | Establishment of platelet bacterial reference strains in BioBall format | from 2019 |
Cystic Fibrosis Institute
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Dr Melanie Albrecht | T cell epithelial crosstalk via IL-17A and IL-22 in CF lung disease | 01.02.19 - 30.04.20 |
FEI | Research Association of the German Food Industry e.V.
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Prof. Dr Stefan Vieths Dr Stephan Scheurer | Investigation of the health-promoting effect of pectins in food allergies | 01.04.19 - 30.09.2021 |
NIH | National Institute of Health
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Prof. Dr Christian Buchholz | Disabling the replication-competent HIV provirus in the reservoir by combined CRISPR-Cas action | 05.04.2019 - 05.04.2023 |
Innovation Committee (Federal Joint Committee)
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Dr Brigitte Keller-Stanislawski | VerSI-MS-PV – Making care safe - Feasibility study on the suitability of different data sources as a basis for improving the pharmacovigilance of innovative therapies using the example of multiple sclerosis | 01.06.2019 - 31.05.2022 |
Health Holland
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Prof. Dr Christian Buchholz | Lentiviral biological pacemakers | 01.03.2020 - 28.02.2022 |
BLE | Federal Office for Agriculture and Food
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Prof. Dr Stefan Vieths Dr Melanie Albrecht | ZeBaP | Development and validation of a cell-based test system for detection of allergens and determination of allergenic potential of processed foods | 01.04.2020 - 31.03.2023 |
DAAD | German Academic Exchange Service / FEBS-Federation of European Biochemical Societies
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Dr Stephan Scheurer | Grants Laura Martin Pedraza: - Molecular characterization of Pru p 9, a novel PR-1 protein responsible for respiratory symptoms in peach tree pollen allergy - Severe peach allergy with different sensitization routes:Pru p 9, a novel major allergen | 01.10.20 - 31.12.20 01.01.21 - 31.03.21 |
DGUV | Statutory Accident Insurance
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Prof. Dr Vera Mahler | Quality assurance of the diagnosis of occupational type I allergies | 01.11.2020 - 31.10.2023 |
Polytechnical Society
| Project Manager | Name of the Project | Duration |
|---|---|---|
| Prof. Dr Zoe Waibler | Analysis of vWF-mediated effects on the immunogenicity of factor VIII products | 01.12.20-30.11.21 |
The totals represent the amount of external funding obtained.